(RPRX) Royalty Pharma - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 30.749m USD | Total Return: 57.6% in 12m
Drug Royalties, Innovation Funding, Development Capital
Total Rating 52
Safety 39
Buy Signal 0.84
Biotechnology
Industry Rotation: -6.3
Industry Rotation: -6.3
Market Cap:
30.7B
Avg Turnover: 193M
Avg Turnover: 193M
Risk 3d forecast
Volatility22.8%
VaR 5th Pctl3.87%
VaR vs Median3.01%
Reward TTM
Sharpe Ratio2.18
Rel. Str. IBD82
Rel. Str. Peer Group72.4
Character TTM
Beta-0.027
Beta Downside-0.185
Hurst Exponent0.343
Drawdowns 3y
Max DD26.46%
CAGR/Max DD0.74
CAGR/Mean DD1.92
EPS (Earnings per Share)
EPS CAGR: -10.10%
EPS Trend: -38.2%
EPS Trend: -38.2%
Last SUE: -0.33
Qual. Beats: 0
Qual. Beats: 0
Revenue
Rev. CAGR: 4.43%
Rev. Trend: 36.2%
Rev. Trend: 36.2%
Last SUE: -0.93
Qual. Beats: 0
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
Supp Ema8, Supp Ema20
Description: RPRX Royalty Pharma
Royalty Pharma plc (RPRX) functions as a specialized financier within the biopharmaceutical sector, acquiring royalty interests in approved drugs and providing capital for clinical development. The company’s portfolio includes royalties on approximately 35 marketed therapies and 20 development-stage candidates across diverse therapeutic areas, including oncology, neuroscience, and rare diseases.
The business model allows RPRX to gain exposure to the commercial success of pharmaceutical products without incurring the high fixed costs associated with manufacturing or direct marketing. By funding late-stage R&D collaborations, such as its partnership for the autoimmune medicine JNJ-4804, the company secures long-term revenue streams through diversified intellectual property assets.
The biopharmaceutical royalty sector typically offers lower volatility than traditional biotech stocks because revenue is tied to top-line sales rather than net profitability or operational overhead. Investors should evaluate the specific cash flow projections and patent expirations on ValueRay to better understand the long-term sustainability of these royalty streams. Founded in 1996 and headquartered in New York, RPRX remains a dominant institutional player in the monetization of pharmaceutical innovation.
- New royalty acquisitions from blockbuster drug pipelines drive future cash flow growth
- Loss of exclusivity for key portfolio assets reduces long-term recurring revenue
- Rising interest rates increase cost of capital for high-value royalty acquisitions
- Successful clinical trial results for development-stage candidates boost portfolio net present value
- FDA approval timelines for partnered therapies dictate timing of milestone payments
Piotroski VR‑10 (Strict)
5.5
| Net Income: 827.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.13 > 0.02 and ΔFCF/TA -1.94 > 1.0 |
| NWC/Revenue: 36.47% < 20% (prev 29.17%; Δ 7.30% < -1%) |
| CFO/TA 0.13 > 3% & CFO 2.65b > Net Income 827.6m |
| Net Debt (8.37b) to EBITDA (1.77b): 4.73 < 3 |
| Current Ratio: 2.66 > 1.5 & < 3 |
| Outstanding Shares: last quarter (559.6m) vs 12m ago -3.20% < -2% |
| Gross Margin: 91.49% > 18% (prev 0.77%; Δ 9.07k% > 0.5%) |
| Asset Turnover: 13.04% > 50% (prev 12.86%; Δ 0.19% > 0%) |
| Interest Coverage Ratio: 5.40 > 6 (EBITDA TTM 1.77b / Interest Expense TTM 336.1m) |
Altman Z''
1.63
| A: 0.04 (Total Current Assets 1.43b - Total Current Liabilities 535.7m) / Total Assets 19.82b |
| B: 0.13 (Retained Earnings 2.51b / Total Assets 19.82b) |
| C: 0.10 (EBIT TTM 1.82b / Avg Total Assets 18.71b) |
| D: 0.25 (Book Value of Equity 2.51b / Total Liabilities 9.88b) |
| Altman-Z'' Score: 1.63 = BB |
What is the price of RPRX shares?
As of May 18, 2026, the stock is trading at USD 52.85 with a total of 4,264,710 shares traded.
Over the past week, the price has changed by +4.52%, over one month by +6.17%, over three months by +17.51% and over the past year by +57.62%.
Over the past week, the price has changed by +4.52%, over one month by +6.17%, over three months by +17.51% and over the past year by +57.62%.
Is RPRX a buy, sell or hold?
Royalty Pharma has received a consensus analysts rating of 4.25.
Therefore, it is recommended to buy RPRX.
- StrongBuy: 4
- Buy: 2
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the RPRX price?
| Analysts Target Price | 59.3 | 12.1% |
Royalty Pharma (RPRX) - Fundamental Data Overview
as of 16 May 2026
P/E Trailing = 28.1053 P/E Forward = 42.0168
P/S = 12.5995
P/B = 2.2657
P/EG = 1.8993
Revenue TTM = 2.44b USD
EBIT TTM = 1.82b USD
EBITDA TTM = 1.77b USD
Long Term Debt = 8.58b USD (from longTermDebt, last quarter)
Short Term Debt = 380.0m USD (from shortTermDebt, last quarter)
Debt = 8.96b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 8.37b USD (from netDebt column, last quarter)
Enterprise Value = 39.10b USD (30.75b + Debt 8.96b - CCE 608.3m)
Interest Coverage Ratio = 5.40 (Ebit TTM 1.82b / Interest Expense TTM 336.1m)
EV/FCF = 14.73x (Enterprise Value 39.10b / FCF TTM 2.65b)
FCF Yield = 6.79% (FCF TTM 2.65b / Enterprise Value 39.10b)
FCF Margin = 108.8% (FCF TTM 2.65b / Revenue TTM 2.44b)
Net Margin = 33.91% (Net Income TTM 827.6m / Revenue TTM 2.44b)
Gross Margin = 91.49% ((Revenue TTM 2.44b - Cost of Revenue TTM 207.6m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 1.97 (Enterprise Value 39.10b / Total Assets 19.82b)
Interest Expense / Debt = 1.05% (Interest Expense 93.7m / Debt 8.96b)
Taxrate = 36.95% (173.0m / 468.3m)
NOPAT = 1.15b (EBIT 1.82b * (1 - 36.95%))
Current Ratio = 2.66 (Total Current Assets 1.43b / Total Current Liabilities 535.7m)
Debt / Equity = 1.30 (Debt 8.96b / totalStockholderEquity, last quarter 6.89b)
Debt / EBITDA = 4.73 (Net Debt 8.37b / EBITDA 1.77b)
Debt / FCF = 3.15 (Net Debt 8.37b / FCF TTM 2.65b)
Total Stockholder Equity = 6.53b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.42% (Net Income 827.6m / Total Assets 19.82b)
RoE = 12.67% (Net Income TTM 827.6m / Total Stockholder Equity 6.53b)
RoCE = 12.02% (EBIT 1.82b / Capital Employed (Equity 6.53b + L.T.Debt 8.58b))
RoIC = 7.51% (NOPAT 1.15b / Invested Capital 15.25b)
WACC = 4.71% (E(30.75b)/V(39.71b) * Re(5.89%) + D(8.96b)/V(39.71b) * Rd(1.05%) * (1-Tc(0.37)))
Discount Rate = 5.89% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares (quarterly) Correlation: -96.61 | Cagr: -3.19%
[DCF] Terminal Value 86.19% ; FCFF base≈2.67b ; Y1≈2.63b ; Y5≈2.71b
[DCF] Fair Price = 163.3 (EV 80.75b - Net Debt 8.37b = Equity 72.38b / Shares 443.3m; r=6.0% [WACC]; 5y FCF grow -2.33% → 3.0% )
EPS Correlation: -38.22 | EPS CAGR: -10.10% | SUE: -0.33 | # QB: 0
Revenue Correlation: 36.22 | Revenue CAGR: 4.43% | SUE: -0.93 | # QB: 0
EPS current Quarter (2026-06-30): EPS=1.27 | Chg30d=-0.44% | Revisions=+0% | Analysts=6
EPS next Quarter (2026-09-30): EPS=1.13 | Chg30d=-3.22% | Revisions=+0% | Analysts=5
EPS current Year (2026-12-31): EPS=5.12 | Chg30d=+1.11% | Revisions=+33% | GrowthEPS=+6.0% | GrowthRev=+5.4%
EPS next Year (2027-12-31): EPS=5.61 | Chg30d=+3.06% | Revisions=+56% | GrowthEPS=+9.7% | GrowthRev=+6.7%
[Analyst] Revisions Ratio: +56%